RxDoctor Payments DataLook up a doctor →

Kanna Dokgo

Family · Honolulu, HINPI 1760843890

Payments from drug & device makers

$26,430in general payments, 2019–2025

Across 1,292 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$3K
  • AstraZeneca$3K
  • Boehringer Ingelheim$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • plus $11K from 38 others

What the payments were for

  • Food & beverage$26,19199%
  • Education$2391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,430 in reported general payments places this provider in the 95th percentile of 466 family providers in Hawaii.

See all family providers in Hawaii

Medicare billing

Part B allowed, 2024
$40,077
Medicare patients
49
Services billed
2,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase91$335,507
ProliaDenosumab181$319,276
VascepaIcosapent Ethyl286$263,553
JanuviaSitagliptin Phosphate101$154,106
FarxigaDapagliflozin Propanediol59$97,557
JardianceEmpagliflozin58$97,165
KerendiaFinerenone56$84,198
TrulicityDulaglutide20$53,798
TrintellixVortioxetine Hydrobromide39$53,438
OzempicSemaglutide28$45,317
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$41,755
LinzessLinaclotide26$30,665
EliquisApixaban16$23,760
LivaloPitavastatin Calcium22$20,817
MyrbetriqMirabegron16$19,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,297$366,172117 claims
AmgenProlia$3,195$319,276181 claims
MerckJanuvia, Janumet Xr$549$171,846114 claims
Boehringer IngelheimJardiance, Tradjenta$2,569$115,54670 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,744$109,52975 claims
BayerKerendia$1,537$84,19856 claims
Lilly USA, LLCTrulicity$1,663$53,79820 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$932$53,43839 claims
Novo NordiskOzempic$1,876$45,31728 claims
GSKTrelegy Ellipta, Shingrix$1,246$44,28149 claims
PfizerEliquis$700$23,76016 claims
Kowa Pharmaceuticals America, Inc.Livalo$148$20,81722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family providers in Hawaii.

Other family in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →